StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.
Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $9.00.
Check Out Our Latest Stock Report on Aptose Biosciences
Aptose Biosciences Price Performance
Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.15. Equities analysts anticipate that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aptose Biosciences
A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.62% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- How Much Can You Make in Stocks in One Month?
- What Are the FAANG Stocks and Are They Good Investments?
- This Is the Top Large-Cap Stock Insiders Are Buying
- Which Wall Street Analysts are the Most Accurate?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.